News

Article

CPAN Year in Review 2023

CPAN Year in Review

In 2023, COA’s Patient Advocacy Network (CPAN) provided advocacy, education, and engagement opportunities in multiple ways. Key outcomes included 14 live advocacy events at community oncology practices including new CPAN chapter launches in Nevada, Ohio, and South Carolina. CPAN advocates and leadership stories were featured in multiple media publications, websites, social media, and COA’s Faces of Community Oncology campaign.

Click here to view CPAN’s Advocacy Year in Review.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of man with text.
An expert highlights the impact of anemia in myelofibrosis and presented Ojjaara as a possible treatment to reduce transfusions and improve outcomes.
After ovarian cancer surgery, Mary Barbera spent three months in rehab before finally returning home, a milestone that marked her emotional recovery.
Terry Gillespie said the hardest parts of her cancer journey were the isolation, the impact of chemotherapy, and how unprepared she felt despite good guidance.
Dr. Erika Hamilton says social media and professional guidelines help patients stay informed about fast-changing breast cancer treatments and advances.
Outpatient CAR T-cell therapy has reduced hospital stays by two-thirds while maintaining safety for those with blood cancers, according to Dr. Olalekan Oluwole.
Related Content
Quality-of-life in lung cancer varies based on treatment and disease stage: © stock.adobe.com.
July 18th 2025

Lung Cancer Study Links Treatment History to Quality-of-Life Differences

Spencer Feldman
Quality-of-life in lung cancer varies, with certain treatments leading to sleep-related issues, pain, and emotional changes depending on disease stage.
The Importance of Spotting Endometrial Cancer
March 18th 2025

The Importance of Spotting Endometrial Cancer

Endometrial cancer is on the rise. Hear survivor Angélica and Eisai Inc.'s Teresa Cronin discuss the Spot Her® initiative, which empowers women to spot early signs. This episode is sponsored by Eisai.
Image of FDA sign.
July 18th 2025

FDA Votes Against Proposed Blenrep Treatment Combo’s for Multiple Myeloma

Ryan Scott
The FDA's Oncologic Drugs Advisory Committee has casted their votes on the utilization of certain treatments in the multiple myeloma patient population.
ROS1+ Non-Small Cell Lung Cancer: Progress in Care
September 20th 2024

ROS1+ Non-Small Cell Lung Cancer: Progress in Care

This episode of the Cancer Horizons podcast features Dr. Jason Porter – a medical oncologist and hematologist at the West Cancer Center and Research Institute and Director of the Lung Cancer Disease research group and is sponsored by Bristol Myers Squibb.
Image of Karen.
July 17th 2025

What’s in a Name? How I Chose ‘Person’ Over ‘Survivor’ After Cancer

Karen Cohn
When asked to choose a word other than “survivor” to describe myself, I chose “person” because cancer does not define who I am.
Image of breast.
July 17th 2025

Enhertu Combo Receives FDA Designation in Metastatic HER2+ Breast Cancer

Ryan Scott
The FDA granted breakthrough therapy designation to first-line treatment with Enhertu plus Perjeta for unresectable or metastatic HER2+ breast cancer.